Posted by Michael Wonder on 19 Jul 2021
EMA starts evaluating the use of Kineret in adult COVID-19 patients at increased risk of severe respiratory failure
19 July 2021 - EMA has started evaluating an application to extend the use of Kineret (anakinra) to include treatment of coronavirus disease 2019 (COVID-19) in adult patients with pneumonia who are at risk of developing severe respiratory failure.
EMA’s CHMP will assess data submitted in the application to decide whether to recommend the extension of indication. Data submitted include results from two ongoing clinical studies investigating the safety and efficacy of the medicine in adult patients hospitalised with COVID-19.
